Literature DB >> 14710899

Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma.

Marie-France Demierre1, Youn H Kim, Herschel S Zackheim.   

Abstract

Although the need for a specific QOL index for MF/SS has been recognized, little work has been done in this area. QOL instruments should address general health concepts, as well as specific issues that are relevant to patients who have MF/SS; a combination of two instruments may be appropriate. Confirming the validity, reliability, and responsiveness to change of a combination of QOL instruments, such as SKINDEX-29 and FACT-G, in patients who have MF/SS will be relevant. For patients who have MF/SS, focusing our efforts on improving the disease and their QOL should translate into improvements that are meaningful to them. Thus, our goal should be to incorporate the findings of QOL research into practice and use the results to guide our practices, as they relate to therapy. Some important considerations are: We must be explicit about what will be done with the information that is obtained about an individual's QOL. We should consider what additional knowledge QOL measures provide that we could not otherwise have. We should be ready for unexpected results, as exemplified by instances where aggressive therapy could result in improved QOL. Although challenges exist in moving forward QOL research in CTCL, the words of wisdom of Tannock bring the concept of QOL into perspective: "When cure remains elusive, it is time to start treating the patient, not just the tumor." A final consideration is that we should not forget the dimension of spirituality, which is especially relevant to patients who have advanced MF/SS. Spirituality is characterized by the capacity to seek purpose and meaning, to have faith, to love, to forgive, and to see beyond current circumstances. Spirituality enables a person to rise above suffering. Unfortunately, research on spirituality is scarce, in part, because of the difficulty in assessing spiritual suffering. Nevertheless, physicians who are caring for patients who have advanced MF/SS should acknowledge the spiritual dimension as an integral component of the dying process.

Entities:  

Mesh:

Year:  2003        PMID: 14710899     DOI: 10.1016/s0889-8588(03)00111-4

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  What factors guide treatment selection in mycosis fungoides and Sezary syndrome?

Authors:  Youn H Kim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Clinical results of the total skin electron irradiation of the mycosis fungoides in adults. Conventional fractionation and low dose schemes.

Authors:  Joanna Kaźmierska
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26

Review 3.  Current and emerging treatment strategies for cutaneous T-cell lymphoma.

Authors:  Frederick Lansigan; Francine M Foss
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

4.  Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Authors:  Frederick Lansigan; Diane M Stearns; Francine Foss
Journal:  Cancer Manag Res       Date:  2010-02-05       Impact factor: 3.989

5.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.